Literature DB >> 25432864

Expression of periplasmic chaperones in Salmonella Typhimurium reduces its viability in vivo.

Michael John Mertensotto1, Jeremy J Drees, Lance B Augustin, Janet L Schottel, Daniel A Saltzman.   

Abstract

The efficacy of live attenuated bacterial vectors is dependent upon the fine-tuning of a strain's immunogenicity and its virulence. Strains are often engineered to deliver heterologous antigens, but soluble expression of recombinant proteins can be troublesome. Therefore, secretion systems or chaperone proteins are routinely used to assist in attaining high levels of functional, soluble protein production. However, the effects of chaperone expression on the virulence of attenuated bacterial vectors have not been previously reported. In anticipation of utilizing periplasmic chaperone proteins to facilitate soluble production of immunomodulatory proteins in an attenuated strain of Salmonella Typhimurium, the production of the chaperones was tested for their effect on both culture growth and bacterial persistence in mouse tissues. Although no effect on growth of the bacteria was observed in vitro, the increased expression of the periplasmic chaperones resulted in over-attenuation of the Salmonella in vivo.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25432864     DOI: 10.1007/s00284-014-0739-9

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  11 in total

1.  Expression of Escherichia coli virulence usher protein attenuates wild-type Salmonella.

Authors:  Xinghong Yang; Zhiyong Suo; Theresa Thornburg; Kathryn Holderness; Ling Cao; Timothy Lim; Nancy Walters; Laura Kellerman; Linda Loetterle; Recep Avci; David W Pascual
Journal:  Virulence       Date:  2012-01-01       Impact factor: 5.882

2.  A system for concomitant overexpression of four periplasmic folding catalysts to improve secretory protein production in Escherichia coli.

Authors:  Martin Schlapschy; Sebastian Grimm; Arne Skerra
Journal:  Protein Eng Des Sel       Date:  2006-05-23       Impact factor: 1.650

3.  Attenuated Salmonella typhimurium invades and decreases tumor burden in neuroblastoma.

Authors:  Sean J Barnett; Leland J Soto; Brent S Sorenson; Brent W Nelson; Arnold S Leonard; Daniel A Saltzman
Journal:  J Pediatr Surg       Date:  2005-06       Impact factor: 2.545

4.  Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains.

Authors:  J E Galán; K Nakayama; R Curtiss
Journal:  Gene       Date:  1990-09-28       Impact factor: 3.688

Review 5.  Engineering the perfect (bacterial) cancer therapy.

Authors:  Neil S Forbes
Journal:  Nat Rev Cancer       Date:  2010-10-14       Impact factor: 60.716

6.  Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination.

Authors:  F Schödel; S M Kelly; D L Peterson; D R Milich; R Curtiss
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

7.  PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae.

Authors:  Wei Xin; Yuhua Li; Hua Mo; Kenneth L Roland; Roy Curtiss
Journal:  Infect Immun       Date:  2009-08-17       Impact factor: 3.441

8.  Attenuated Salmonella typhimurium with interleukin 2 gene prevents the establishment of pulmonary metastases in a model of osteosarcoma.

Authors:  Brent S Sorenson; Kaysie L Banton; Natalie L Frykman; Arnold S Leonard; Daniel A Saltzman
Journal:  J Pediatr Surg       Date:  2008-06       Impact factor: 2.545

9.  Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli.

Authors:  Ario de Marco
Journal:  Microb Cell Fact       Date:  2009-05-14       Impact factor: 5.328

10.  Optimizing heterologous protein production in the periplasm of E. coli by regulating gene expression levels.

Authors:  Susan Schlegel; Edurne Rujas; Anders Jimmy Ytterberg; Roman A Zubarev; Joen Luirink; Jan-Willem de Gier
Journal:  Microb Cell Fact       Date:  2013-03-12       Impact factor: 5.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.